Genotype-Guided Risk Stratification of Mitral Valve Surgery in Marfan Syndrome
JACC · 2026-06 · 87 (24) · 3452-3463
DOI: 10.1016/j.jacc.2026.01.059 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-06. Verfasst von Yuki Kawashima und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Marfan Syndrome, Mitral Valve, Fibrillin-1, Mitral Valve Insufficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: U.S. Food and Drug Administration.
Abstract (Originalsprache)
BACKGROUND: Although genotype-based risk stratification for aortic disease has been extensively studied in Marfan syndrome (MFS), mitral valve disease has received less attention despite being a major cardiovascular complication requiring surgery in up to 16% of cases. OBJECTIVES: The authors aimed to evaluate genotype-specific differences in mitral valve disease progression and surgical intervention to inform precision medicine approaches in MFS. METHODS: This retrospective cohort study included 437 MFS patients with pathogenic FBN1 variants (2006-2024). Variants were classified by molecular mechanism (premature termination codon [PTC] variants vs in-frame variants [IFVs]) and genomic location. Time-to-event cause-specific analysis assessed genotype-specific risks for mitral valve surgery. RESULTS: Among 437 patients, 206 (47.1%) had PTC variants and 231 (52.9%) IFVs. Mitral valve surgery was performed in 38 patients (8.7%) at median age of 25.0 years. Among IFVs, those within the DNCD region (Dominant Negative variants affecting Cysteine residues and in-frame Deletions; exons 26-37 and 44-50) showed markedly higher 30-year cumulative incidence of mitral valve surgery (23.8% [95% CI: 11.7%-35.9%] vs 1.24% [95% CI: 0.0%-2.96%] in other IFVs and 3.20% [95% CI: 0.66%-5.77%] in PTC variants). IFVs within the DNCD region showed the earliest onset of mitral valve surgery in childhood/adolescence, whereas PTC variants demonstrated delayed risk beginning around age 30 years. Cox analysis confirmed IFVs within the DNCD region had highest risk of mitral valve surgery for patients aged ≤30 years (HR: 7.83 vs PTC variants; 95% CI: 3.14-19.57; P < 0.001) with robust discrimination (C-index = 0.725). CONCLUSIONS: IFVs within the DNCD region confer the highest risk for mitral valve surgery with distinct age-dependent patterns. These findings enable genotype-guided risk stratification with age-specific surveillance protocols, potentially transforming clinical management in MFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
- Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan; Marfan Syndrome Center, The University of Tokyo Hospital, Tokyo, Japan; The Institute of Medical Science, The University of Tokyo, T…
- Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan; Marfan Syndrome Center, The University of Tokyo Hospital, Tokyo, Japan.
- Marfan Syndrome Center, The University of Tokyo Hospital, Tokyo, Japan; Department of Orthopaedic Surgery, The University of Tokyo Hospital, Tokyo, Japan.
- Marfan Syndrome Center, The University of Tokyo Hospital, Tokyo, Japan; Department of Cardiovascular Surgery, The University of Tokyo Hospital, Tokyo, Japan.
- Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan; Marfan Syndrome Center, The University of Tokyo Hospital, Tokyo, Japan. Electronic address: inuzukar-tky@g.ecc.u-tokyo.ac.jp.
Förderung
- U.S. Food and Drug Administration
Zitieren
APA
Kawashima, Y., Takeda, N., Omori, A., Nogimori, Y., Shiraga, K., Masuda, H., Yagi, H., Taniguchi, Y., Yamauchi, H., Ono, M., & Inuzuka, R. (2026). Genotype-Guided Risk Stratification of Mitral Valve Surgery in Marfan Syndrome. JACC, 87(24), 3452-3463. https://doi.org/10.1016/j.jacc.2026.01.059
Vancouver
Kawashima Y, Takeda N, Omori A, Nogimori Y, Shiraga K, Masuda H, et al. Genotype-Guided Risk Stratification of Mitral Valve Surgery in Marfan Syndrome. JACC. 2026;87(24):3452-3463. doi:10.1016/j.jacc.2026.01.059
BibTeX
@article{Kawashima2026,
author = {Kawashima, Yuki and Takeda, Norifumi and Omori, Akiharu and Nogimori, Yoshitsugu and Shiraga, Kazuhiro and Masuda, Hitomi and Yagi, Hiroki and Taniguchi, Yuki and Yamauchi, Haruo and Ono, Minoru and Inuzuka, Ryo},
title = {Genotype-Guided Risk Stratification of Mitral Valve Surgery in Marfan Syndrome},
journal = {JACC},
year = {2026},
volume = {87},
number = {24},
pages = {3452--3463},
doi = {10.1016/j.jacc.2026.01.059}
}
EUVIMED